Replies to post #243906 on Biotech Values

[nsomniyak]

I dug around after my post to you and I found this post on this board (dated 7/18/22)

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169432301&txt2find=sesn

The author states that the Roche payment would be (up to?) $30M, or about .15 per share, if Roche initiates a Phase 3 trial on EBI-031 by the end of 2026. Assuming the share structure has not changed since then (?) that would imply a CVR value of up to .15, would which then need to be discounted in two ways - the payment is not certain and might not occur until 27 months from now.

I have not personally validated those numbers.